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ABSTRACT
Phage FC31 integrase has potential as a means
of inserting therapeutic genes into specific sites in
the human genome. However, the possible interac-
tions between FC31 integrase and cellular proteins
have never been investigated. Using pLexA-FC31
integrase as bait, we screened a pB42AD-human
fetal brain cDNA library for potential interacting
cellular proteins. Among 61 positives isolated
from 10
6 independent clones, 51 contained DAXX
C-terminal fragments. The strong interaction
between DAXX and FC31 was further confirmed by
co-immunoprecipitation. Deletion analysis revealed
that the fas-binding domain of DAXX is also the
region for FC31 binding. Hybridization between a
FC31 integrase peptide array and an HEK293 cell
extract revealed that a tetramer, 451RFGK454, in the
C-terminus of FC31 is responsible for the inter-
action with DAXX. This tetramer is also necessary
for FC31 integrase activity as removal of this tetra-
mer resulted in a complete loss of integrase activity.
Co-expression of DAXX with FC31 integrase in a
HEK293-derived FC31 integrase activity reporter
cell line significantly reduced the FC31-mediated
recombination rate. Knocking down DAXX with a
DAXX-specific duplex RNA resulted in increased
recombination efficiency. Therefore, endogenous
DAXX may interact with FC31 causing a mild
inhibition in the integration efficiency. This is the
first time that FC31 was shown to interact with an
important cellular protein and the potential effect of
this interaction should be further studied.
INTRODUCTION
Gene therapy remains the most promising if not the only
approach to treating genetic diseases. The safety concerns
of gene therapy have been heightened by the discovery of a
leukemia-like disorder in several patients treated with a
retrovirus vector, due to an insertional mutagenesis (1). To
minimize the potential risk of gene therapy, therapeutic
genes should be integrated at speciﬁc sites proven to be safe.
While homologous recombination gives rise to precise site-
speciﬁcity, the low efﬁciency limits its clinical application
(2). Alternatively, integrases mediate site-speciﬁc insertions
into the genome by recognizing speciﬁc sequences. Site-
speciﬁc recombination systems are ubiquitous throughout
prokaryotes but are rare in mammals (3). Some phage recom-
binases such as Cre are able to insert a gene into a speciﬁc
site (loxP) and have been employed in engineering mamma-
lian cells (4,5). However, these recombination systems
require pre-insertion of their substrate DNA sequences,
such as the loxP site for Cre, located in the target region in
mammalian genomes, which limits their potential clinical
applications. Phage FC31 integrase belongs to the serine
recombinase family that mediates site-speciﬁc recombination
between two short recognition sites, attB and attP (3,6).
Recombination occurs when these two att sites are present
in two different DNA molecules and the attB serves as the
donor to be inserted into the attP (3). Interestingly, it has
been discovered that FC31 integrase can also mediate
recombination at a limited number of sites in mammalian
genomes (7). These ‘pseudo-att’ sites have been proposed
as potential targets for site-speciﬁc gene insertion using the
FC31 integrase-based system (8–11). Several studies have
demonstrated the usefulness of the FC31 integrase system in
gene therapy. A FC31-integrase-mediated gene insertion into
a human myoblast genome resulted in a 15-fold increase in
stable expression compared to that without integrase (12).
Similarly, coinjection of plasmid-expressing FC31 in the
mdx mouse resulted in 5- to 10-fold higher levels of sustained
luciferase expression as well as dystrophin expression (13).
However, potential interactions between FC31 and proteins
in mammalian host cells have never been studied carefully.
This issue has become particularly important as it has been
reported that FC31 integrase induced a high frequency of
hepatocyte dysplasia after the integrase system was used to
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into the livers of mice affected with hereditary tyrosinemia
type 1 (14).
To test the hypothesis that FC31 integrase may
interact with cellular proteins, we employed a yeast-two-
hybridization assay to detect cellular proteins that interact
with FC31 integrase. We report here that FC31 can strongly
bind to an important cellular protein, DAXX, as evidenced
by the results of yeast-two-hybridization and co-immuno-
precipitation. We have identiﬁed the binding regions in
both proteins and the functional interaction between DAXX
and FC31 were also demonstrated by reduced FC31
integrase activity in DAXX-overexpressing cells.
MATERIAL AND METHODS
Plasmid construction
To construct a pLexA-FC31 bait plasmid, the open reading
frame (ORF) of FC31 integrase was ampliﬁed from a
pCMVInt plasmid (kindly provided by Prof. M. P. Calos)
with a pair of primers: 50-gaggatcctgacacaaggggttgtgac-
30 and 50-ccgctcgagcgccgctacgtcttccgtg-30. The PCR product
was inserted into the plasmid pLexA (Clontech) between
the BamHI and XhoI sites. The N-terminal catalytic-activity-
containing fragment (1–235 amino acid toward CAC93948)
and C-terminal fragment (237–613 amino acid towards
CAC93948) were ampliﬁed with primers 50-gaggatcctgacaca-
aggggttgtgac-30,5 0-ccgctcgagcgcttacaaagccccgtgatgctg-30 and
50-gaggatcctggacgctgacgccgtgccg-30,5 0-ccgctcgagcgccgctac-
gtcttccgtg-30. The fragments were then inserted into the
pLexA plasmid between BamHI and XhoI to produce
the plasmids pLexA-FC31 (1–235) and pLexA-FC31
(237–613). Both these plasmids were used in a yeast-mating
test for locating the interacting fragment of FC31 integrase.
pB42AD-DAXX(572–625) and pB42AD-DAXX(625–
740) were used for determining the FC31-interacting frag-
ment on DAXX. These fragments were ampliﬁed from a
pB42AD fetal brain cDNA library (Clontech) with the
primers 50-gcgaattcaacatggaagctttgcccctggatac-30,5 0-ccgctcg-
agcggaccagaatctccccagttgtg-30 and 50-gcgaattcaacatgtctggtcc-
cccctgcaaaaaatc-30,5 0-ggagacttgaccaaacctctggcg-30. The PCR
products were inserted into the site between EcoRI and XhoI
in the pB42AD plasmid (Clontech).
The above obtained FC31 ORF was also subcloned into
pEGFP-C2 (Clontech) between BamHI and XhoI sites in
the frame with the C-terminus of EGFP to generate
pEGFP-FC31 that expresses EGFP-FC31 fusion protein. A
construct pFC31-EGFP expressing C-terminal fused FC31
fusion protein was produced similarly.
The ORF of human DAXX was obtained from a human
fetal brain cDNA library (Clontech) by ampliﬁcation with
primers 50-gagaattcacaatggccaccgctaacagc-30 and 50-gaggatc-
ctcagagtctgagagcacg-30. The cDNA was inserted into
pDsRed-N1 (Clontech) between EcoRI and BamHI to
generate pDAXX-DsRed that expresses DAXX-DsRed fusion
protein. Plasmids that express mutant FC31s, namely,
pLexA-FC31(Del451–454), pLexA-FC31(R451H) and
pLexA-FC31 (K454N), were generated by a PCR-based
point speciﬁc mutation strategy with the primers shown
in Table 1.
The above mutant FC31s were also ampliﬁed with primers
50-gaggatcctatgacacaaggggttgtgac-30 and 50-ccgctcgagcgccgc-
tacgtcttccgtg-30 and inserted into pcDNA3.0 (Invitrogen)
between BamHI and XhoI for expression and determination
of the catalytic activity of mutant FC31.
The plasmids mentioned above were all veriﬁed by
sequencing analysis.
Yeast-two-hybridization assay
The MATCHMARKER LexA two-hybrid system was
purchased from Clontech. Yeast-two-hybridization was
performed in a standard two-step protocol provided by the
manufacturer. All isolated positive clones were ampliﬁed
with the uniform pB42AD sequence primers (50-ccagcctcttgc-
tgagtggagatg-30;5 0-ggagacttgaccaaacctctggcg-30) and the
PCR products were sequenced with the same primers.
For locating the interacting fragment on DAXX,
yeast-mating tests between pB42AD-DAXX(572–625)/
pB42AD-DAXX(627–740)-transferred EGY48[p8opLacZ]
and pLexA-FC31-transferred YM4271 were performed
according to a standard yeast-mating protocol provided by
the manufacturer.
The yeast-mating test was also used to determine the inter-
acting fragment on FC31 integrase. Either pLexA-FC31(1–
235), pLexA-FC31(237–613), pLexA-FC31(Del451–454),
pLexA-FC31(R451H) or pLexA-FC31(K454N) was used
to correspondingly transfect YM4271, which was then mated
with pB42AD-DAXX(527–740) EGY48[p8opLacZ] yeast
cells.
Co-immunoprecipitation
Co-immunoprecipitation was employed to verify the interac-
tion between FC31 integrase and cellular protein DAXX.
The HEK293 cells were maintained in DMEM (Gibco)
medium with 10% fetal calf serum, 100 U/ml penicillin,
and 100 U/ml streptomycin at 37 C in a humidiﬁed
atmosphere of 5% CO2. The cells were transfected with
pEGFP-FC31 or a control plasmid pEGFP-N3 (Clontech)
Table 1. The primers designed for point specific mutation of FC31 integrase
Mutants Uniform ORF primers Mutation primers
Del451–454 50-gaggatcctgacacaaggggttgtgac-30;
50-ccgctcgagcgccgctacgtcttccgtg-30
50-ctgtgggaagccgcccgactcactgaggcgcctgag-30;
50-ctcaggcgcctcagtgagtcgggcggcttcccacag-30
K454N 50-gaggatcctgacacaaggggttgtgac-30;
50-ccgctcgagcgccgctacgtcttccgtg-30
50-ctgtgggaagccgcccgacgcttcggcaacctcactgaggcgcctgag-30;
50-ctcaggcgcctcagtgaggttgccgaagcgtcgggcggcttcccacag-30
R451H 50-gaggatcctgacacaaggggttgtgac-30;
50-ccgctcgagcgccgctacgtcttccgtg-30
50-ctgtgggaagccgcccgacacttcggcaagctcactgaggcgcctgag-30;
50-ctcaggcgcctcagtgagcttgccgaagtgtcgggcggcttcccacag-30
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the cells were harvested and lysed with 1 ml lysis buffer
(20 mM Tris pH 7.5, 100 mM NaCl, 0.5% NP-40, 0.5 mM
EDTA, 0.5 mM PMSF, 0.5% protease inhibitor cocktail
(Sigma)). Ten micrograms of mouse anti-GFP monoclonal
antibody (NeoMarkers) were added to 1 ml of each cell
lysate. After incubation with end-over-end mixing for 2 h
at 4 C, 10 ml of pre-washed protein A/G Sepharose (Santa
Cruz) were added to each extract and shaken for 1 h at
4 C. Next, the immunoprecipitates were washed three times
with the lysis buffer. The pellets were then separated on
SDS–PAGE and transferred to a nitrocellulose membrane.
The blot was detected using rabbit anti-human DAXX anti-
body (Santa Cruz) followed by horseradish-peroxidase-
conjugated anti-rabbit antibody (Sigma) and the bands
were visualized using an enhanced chemiluminescence
immunoblotting detection kit (Amersham).
FC31 peptide array analysis
Three FC31 peptide arrays (12, 15 and 20 mers) were gener-
ated and probed with DAXX to determine the DAXX binding
region in FC31. Cellulose-bound overlapping peptides
derived from FC31 integrase were synthesized using an
AutoSpot robot (Intavis Bioanalytical Instruments).
The basic lengths of the spotted fragments for the three
arrays were 12, 15 and 20 residues, respectively. Each neigh-
boring peptide shifted two residues towards the C-terminus.
The arrays were incubated with a cell lysate of 5 · 10
7
HEK293 cells in 10 ml of lysis buffer at 4 C overnight.
The membranes were then incubated with a rabbit anti-
human DAXX polyclonal antibody (Santa Cruz) followed
by horseradish-peroxidase-conjugated anti-rabbit antibody
(Sigma). The bound proteins were visualized using enhanced
chemiluminescence immunoblotting detection reagents
(Amersham). For controls, the membranes were processed
identically but incubation with the cell lysate was omitted.
Intracellular localization of DAXX and FC31 integrase
The subcellular locations of DAXX and FC31 integrase were
determined in HEK293 cells. Fusion plasmids, pDAXX-
DsRed, pEGFP-FC31 and pFC31-EGFP were used to trans-
fer HEK293 for the location of FC31 integrase and DAXX,
respectively. The cells were transfected with the plasmids
above using Lipofectamine (Invitrogen). At 24 h post-
transfection, the cells were observed under a confocal ﬂuores-
cent microscope (TSC SP2, Leica). The nuclei were strained
with DAPI as a control. The ﬂuorescence of GFP, RFP and
DAPI was observed at wavelengths of 488, 543 and 405 for
excitation and 510, 582 and 461 for emission, respectively.
FC31 integrase activity assay
FC31 integrase activity in Escherichia coli was determined
using a pBCPB-(kindly provided by Prof. M.P. Calos)
based system (8). Brieﬂy, plasmid containing FC31 integrase
or its mutant cDNAs was co-transformed with pBCPB into
E.coli DH5a-competent cells. The cells were plated on an
LB agar medium with ampicillin (50 mg/ml), chloram-
phenicol (50 mg/ml) and X-gal (40 mg/ml). Recombination
through active FC31 integrase causes deletion of the
beta-glactosidase gene from pBCPB and gives rise to white
colonies. The ratio of the number of white colonies to that
of total colonies was calculated 24 h later as an index of
integrase activity.
FC31-mediated integration in mammalian cells was mea-
sured using an HEK293-derived FC31 integration reporter
cell line, PB[EGFP], which was created in our laboratory.
PB[EGFP] contains a genomically inserted single copy struc-
ture of pCMV-attB-BGH poly A-attP-EGFP. In the presence
of FC31, integrase-mediated recombination between attB
and attP sites removes bGH poly A from the inserted struc-
ture, resulting in EGFP expression. At 48 h post-transfection,
the cells were harvested and percentages of EGFP-expressing
cells were determined by ﬂow cytometery. Overexpression
of DAXX was accomplished by co-transfecting pDAXX-
DsRed1 with pCMVInt. The plasmid pDsRed1-N1 that
contains no DAXX was used as a control construct. Mean-
while, Endogenous expression of DAXX was knocked
down by transfection with a DAXX-speciﬁc duplex RNA
(50-GGAGUUGGAUCUCUCAGAAdTdT-30;5 0-UUCUGA-
GAGAUCCAACUCCdTdT-30) (15), which reduced the
DAXX protein expression level by  75%, as estimated by
western blot analysis with a human DAXX-speciﬁc antibody.
As a control, a human non-silencing duplex RNA (50-UUAA-
GUAGCUUGGCCUUGAdTdT-30;5 0-UCAAGGCCAAGC-
UACUUAAdTdT-30)(GeneChem, China) was used.
RESULTS
Results of yeast-two-hybridization and
co-immunoprecipitation indicated a strong
interaction between FC31 and DAXX
We initially used pLexA-FC31 as a bait to screen a pB42AD-
based human fetal brain cDNA library for potential FC31
integrase interacting proteins. Sixty-one positives were iso-
lated from 10
6 independently screened clones and sequenced.
Fifty-one out of the 61 positive clones corresponded with the
C-terminus of DAXX sequence, from 527 to 730 amino acid
(Figure 1A).
The interaction between FC31 integrase and DAXX was
veriﬁed with co-immunoprecipitation analysis. HEK293
cells were transfected with either pEGFP-FC31 that
expressed an EGFP-FC31 fusion protein or a control cons-
truct pEGFP-N3 containing the EGFP only. A mouse anti-
GFP antibody was able to precipitate DAXX from the cell
lysate of HEK293 transfected with pEGFP-FC31 but not
with pEGFP-N3 (Figure 1B).
Characterization of interacting fragments of FC31
integrase and DAXX
We then attempted to locate the key fragment that mediates
the interaction between FC31 integrase and DAXX. Both
the C-terminus (237–613) and N-terminus (1–235) of FC31
protein were fused to the LexA DNA binding domain. The
yeast-mating test revealed that the C- but not the N-terminus
of the integrase is necessary for the interaction. To further
narrow down the exact region in the C-terminus of FC31,
peptide arrays displaying overlapping fragments of FC31
that covered the entire sequence of the FC31 protein were
utilized for the binding of endogenous DAXX from the
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bound DAXX was detected with an anti-DAXX antibody.
The strongest immunoreactivity was found predominantly at
spot 222–226 on 12-residue arrays, spot 221–226 on
15-residue arrays and spot 218–226 on 20-residue arrays
(Figure 1C). Interestingly, the positive spots from the three
FC31 arrays shared a common corresponding region of a tet-
ramer, 451RFGK454, indicating that it was probably the frag-
ment in FC31 responsible for DAXX binding (Figure 1D).
For further characterizing the binding site of FC31, we
generated three mutant FC31 constructs, including an
Arg
451–His
451 point mutation (pLexA-FC31(R451H)), a
Lys
454–Asn
454 point mutation (pLexA-FC31(K454N)) and
one with a deletion of the tetramer 451–454 (pLexA-
FC31(Del451–454)). The yeast-two-hybrid assay showed
no interaction between pLexA-FC31(Del451–454) and
DAXX. However, mutations at the Arg
451 (pLexA-
FC31(R451H)) or Lys
454 (pLexA-FC31(K454N)) residue
of FC31 did not alter its binding to DAXX. (Figure 1A).
To localize the region in DAXX that binds to FC31, a
pB42AD construct containing a DAXX with a deletion of
amino acid 627–740 was generated for the yeast-mating
Figure 1. Interaction between FC31 integrase and human DAXX. (A) Yeast two-hybrid analysis was conducted using FC31-integrase-derived pLexA fusion
plasmids as bait, a human fetal cDNA-derived pB42AD library and two human DAXX-derived pB42AD fusion plasmids as prey. The overlapping open reading
frames correspond to human DAXX. (B) Cell lysates of pEGFP-FC31-transfected and pEGFP-N3-transfected HEK293 cells were each incubated with a mouse
anti-GFP binding protein on A/G agarose beads. Samples were analyzed by western blotting with a rabbit anti-human DAXX antibody. An unknown protein with
higher molecular weight was also recognized by the anti-DAXX antibody. However, it is probably non-specific by a cross-reaction of the polyclonal antibody as
it is present in all the samples. (C) Three FC31 integrase overlapping peptide arrays with different lengths of peptide (12, 15 and 20mers) for localization of the
DAXX interacting region on FC31. Serial numbers of spots that were positive for DAXX binding were labeled. (D) Amino acid sequences of the peptide spots
corresponding to the array shown in C. The DAXX binding tetramer is indicated by underlining.
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completely abolished its binding to FC31 (Figure 1A).
Furthermore, a construct containing a fragment of DAXX
(627–740) (pB42AD-DAXX (627–740), Figure 1A) was
sufﬁcient for binding to FC31. These results clearly demon-
strated that the tetramer 451RFGK454 in the FC31 integrase
and the region between 627 and 740 amino acid in DAXX are
crucial for the interaction between the two proteins.
Intracellular localization of FC31 and DAXX
Plasmids of pDAXX-DsRed, pEGFP-FC31, pFC31-EGFP
and pEGFP that express DAXX-DsRed, N- or C-terminal
fused EGFP/FC31 fusion proteins and EGFP alone, respec-
tively, were used for intracellular localization of FC31 inte-
grase and DAXX. As shown in Figure 2A, punctates of red
ﬂuorescent DAXX-DsRed fusion protein were present predo-
minantly in the nucleus. In contrast, both N- and C-terminal
fused EGFP/FC31 fusion protein were mainly localized in
the cytoplasm (Figure 2A–C). Meanwhile, EGFP alone was
distributed evenly in both the cytoplasm and nucleus, sug-
gesting that FC31 dominated the intracellular localization
of the fusion proteins.
The 451RFGK454 site is essential for FC31 integrase
activity
To determine whether the DAXX binding site, 451RFGK454,
on FC31 is involved in the activity of the integrase, pcDNA-
FC31, pcDNA-FC31(Del451–454), pcDNA-FC31(R451H)
or pcDNA-FC31(K454N) was co-transformed with pBCPB
into E.coli DH5a-competent cells. Twenty-four hours later,
pcDNA-FC31(R451H) gave rise to a similar number of posi-
tive colonies as that of pcDNA-FC31, (51.20% ± 1.60% ver-
sus 49.98% ± 2.63%). Thus, mutation from Arg
451 to His
451
in FC31 did not affect the integrase activity. In contrast, no
white colonies were seen in samples transformed with
pcDNA-FC31(Del451–454) and pcDNA-FC31(K454N),
indicating that 451RFGK454 and Lys
454 are essential for
the activity of FC31 integrase.
DAXX inhibits FC31-mediated integration
The FC31 activity reporter cells PB[EGFP] transfected with
pCMVInt gave rise to a recombination rate in the total trans-
fectants of 20.30% ± 1.04% when the transfection efﬁciency
averaged 47.50% ± 3.04%. Co-expression of pDAXX-DsRed
but not a control plasmid pDsRed1 signiﬁcantly reduced the
recombination rate by 39.40 ± 0.98% (P < 0.01). On the other
hand, co-transfection with pCMTInt and a DAXX-speciﬁc
duplex small RNA resulted in an increase in GFP-expressing
cells of 24.24 ± 0.95% (P < 0.05). However, this increased
rate of recombination was not seen in cells co-transfected
with a human non-silencing duplex small RNA (82.25 ±
1.05% of the control, P > 0.09, Figure 3 column D). These
results indicated that the endogenous DAXX can slightly
inhibit the integration efﬁciency of FC31 in HEK293 cells
(Figure 3).
DISCUSSION
DAXX is known for its distribution in nucleus domain 10
(ND10) and it relocates to the cytoplasm through nuclear
export in response to certain signals (16–18). Consistent
with this, we found that punctate DAXX-DsRed ﬂuorescence
was mainly localized in the nucleus. Meanwhile, the
GFP-FC31 fusion protein was predominantly located in the
cytoplasm. The GFP fusion protein possesses the same sub-
cellular distribution as FC31 itself, and was localized with
an antibody against FC31 protein (to be published else-
where). The predominant cytoplasmic localization of FC31
was also consistent with an earlier observation that adding
a nuclear localization signal could increase the integration
Figure 2. Subcellular localization of DAXX and FC31 integrase. (A) pDAXX-DsRed and pEGFP-FC31 fusion protein constructs were co-transfected into
HEK293 cells. (B) HEK293 cells transfected with pEGFP-FC31 alone. (C) HEK293 cells transfected with a FC31 construct with C-terminal fused EGFP
(pFC31-EGFP) alone. (D) Cells transfected with pEGFP alone. Expressed fluorescent GFP and DsRed were observed under a confocal microscope. The nuclei
were stained by DAPI (40X).
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localization between DAXX and FC31 integrase with ﬂuo-
rescent microscopy in contrast to the high afﬁnity between
the two proteins demonstrated by yeast-two-hybrid screening
and co-immunoprecipitation may be attributed to the insufﬁ-
cient sensitivity of ﬂuorescence microscopy and/or low
amounts of the co-localized proteins. Strong red ﬂuorescence
of the DAXX-DsRed fusion protein in the nucleus may mask
the green ﬂuorescence of EGFP-FC31 fusion protein due to
the relatively small amount of intranuclear-localized FC31
and vice versa for the cytoplasmic-localized DAXX-DsRed.
Indeed, low levels of EGFP ﬂuorescence seemed present in
the nuclei of a few cells under microscope although the ﬂuo-
rescence failed to show in microphotographs. This argument
is supported by the fact that, although little EGFP-FC31
green ﬂuorescence was seen in the nuclei, FC31-mediated
site-speciﬁc integration, which only takes place in the
nucleus, was found in a signiﬁcant percentage of FC31 activ-
ity reporter cells. Furthermore, a functional interaction
between the two proteins was also demonstrated by both
overexpression and knockdown DAXX in HEK293 cells. It
is especially noteworthy that the FC31-mediated integration
rate was increased by 24% in DAXX siRNA-treated cells
because this suggests the existence of an endogenous interac-
tion between the two proteins. The relatively mild increase in
the FC31 integration efﬁciency may be attributed to the
extreme abundance of DAXX in the nucleus causing incom-
plete DAXX knock down by the siRNA. However, it is
important to determine whether FC31 predominantly local-
ized in the cytoplasm can interfere with the function of
DAXX when the latter is translocated to the cytoplasm
upon activation by other cellular signals.
The mutational analysis of FC31 protein showed that the
DAXX binds to 451RFGK454 in the FC31. The integrase
activity assay further indicated that the tetramer is essential
for integrase activity and therefore, binding to this region
by DAXX may inhibit the integrase. It is worth pointing
out that previous studies have indicated that the catalytic
activity of FC31 was located between residues 1 and 120
at the N-terminus of the protein, and that the Ser
12 is the puta-
tive catalytic serine while the putative DNA binding domain
is possibly at the C-terminus (20,21). We showed here that
451RFGK454 is crucial for the integration activity of
FC31. However, the exact role of this region remains to be
investigated.
Our yeast-mating test showed that only the construct con-
taining the DAXX 627–740 fragment, but not DAXX 573–
627, interacted with FC31, suggesting that this 627–740
amino acid region is crucial for the DAXX-FC31 interaction.
Interestingly, the same domain is also well known for its
interaction with other cellular proteins including Fas. To
date, more than 20 proteins have been reported to interact
with DAXX resulting in a broad range of effects including
apoptotic regulation, transcriptional regulation, chromatin
remodeling, involvement in signal pathways and regulation
of the interaction between virus and host cells (22,23).
DAXX was also reported to bind to the integrase of Avian
Sarcoma Virus (ASV) (24). Interestingly, we found that
DAXX binds to FC31 through the same domain as that for
binding to ASV integrase. More importantly, the interaction
between DAXX and ASV integrase causes suppression of
viral replication, which was also reported in human
cytomegalovirus-infected cells where DAXX had also been
found to interact with a viral protein, pp71, causing inhibition
of viral replication (25–27), suggesting that DAXX may play
a role in cellular defense against viral infection.
The present study was the ﬁrst to reveal that a phage inte-
grase, FC31, interacts with an important cellular protein,
Figure 3. Effects of DAXX overexpression and siRNA knock down on efficiency of FC31-integrase-mediated recombination in the FC31 activity reporter cells
PB[EGFP]. The efficiency of recombination was first calibrated using the transfection efficiency in each culture and then expressed as percentages of the cultures
transfected with pCMVInt only. PB[EGFP] reporter cells were transfected with A, pCMVInt, B, pCMVInt/pDsRed1, C, pCMVInt/pDAXX-DsRed1, D,
pCMVInt/non-silencing siRNA, and E, pCMVInt/siDAXX. *P < 0.05, **P < 0.01.
Nucleic Acids Research, 2006, Vol. 34, No. 21 6303DAXX. The strong binding of FC31 to DAXX indicates the
importance of understanding potential interactions between
the integrases and cellular proteins in mammalian cells
since the information gained would aid in developing a
gene therapy strategy for site-speciﬁc genomic insertion.
On the other hand, the inhibitory effect of DAXX on viral
proteins across a wide range of species (from phage, avian
to human viruses) suggests that DAXX might play a role in
maintaining the stability of the genome through preventing
extrinsic DNA integration.
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